tbuckley/cabot-search huggingface dataset:
KOCH, VIRCHOW AND TAIT.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase II, single arm clinical trial involving an alternative cancer treatment psorinum therapy in patients with metastatic renal cell carcinoma.
Authors: Aradeep Chatterjee, Amitava Chakraborty, Ashim Kumar Chatterjee, Sudin Bhattacharya, Radhe S. Bhakta, Jaydip Biswas
Journal: Journal of Clinical Oncology (2014)

3065 Background: We prospectively studied the clinical efficacy of an alternative cancer treatment “psorinum therapy” in treating metastatic renal cell carcinoma (mRCC). Methods: Our study was phase II, open level, single arm and single stage. Participants’ eligibility criteria included (1) pathological confirmation of the malignancy (2) metastatic disease status (3) no prior conventional cancer treatments (4) Karnofsky performance status between 40- 70%. The primary outcome measures of the study were (1) to assess the radiological tumor response rate (using CT scanning procedure and following the RECIST criteria; (2) to assess how many participants survived at least 1 yr, 2yrs, 3yrs, 4yrs and finally, after 5 years. The secondary outcome measure was to assess the side effects of the investigational anti- cancer drug (psorinum) if any. Psorinum (an alcoholic extract of scabies slough and pus cells) was administered orally at a dose of 0.04ml/ Kg body weight/ day as a single dose on an empty stomach for a complete course duration of 2 yrs to all the participants along with allopathic and homeopathic supportive cares. Results: 78 participants included in the final analysis at the end of the study. According to the RECIST criteria complete response occurred in 11 (14.10%) cases and partial response occurred in 29 (37.18%) cases. 64 (82.05%) of them survived at least 1yr, 48 (61.54%) survived at least for 2yrs, 41 (52.56%) survived at least 3yrs, 29 (37.18%) survived at least 4yrs, 24 (30.77%) survived at least for 5yrs. These participants didn't receive conventional or any other investigational cancer treatments. Conclusions: The results of the study show clinical efficacy of psorinum therapy in treating patients with mRCC. The investigational drug psorinum is non- toxic. Randomized controlled clinical trial should be conducted for further investigation of this alternative cancer treatment in treating metastatic renal cell carcinoma to integrate it into the mainstream oncology.
Membership of Committees on Education (as of June 30, 1989)
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pioneers in Providing a Competency Inventory
Authors: D. F. Phillips
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
European Seminar and Lecture Course on Alcoholism
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE BUFF SUBSCRIPTION BLANK
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Studies on Specific Transplantation Resistance to Polyoma-Virus-Induced Tumors. I. Transplantation Resistance Induced by Polyoma Virus Infection&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Hans Olof Sjögren
Journal: JNCI Journal of the National Cancer Institute (1964)

Forty-three polyoma tumors and 35 nonpolyoma tumors were tested for susceptibility to the polyoma-virus-induced transplantation resistance of mice. All polyoma tumors but 1 were susceptible, while 33 of the nonpolyoma tumors were not. The susceptible polyoma tumors included all morphologically different types tested and also 1 tumor induced in vitro. The unsusceptible tumor was a thymoma morphologically of the same type as 4 susceptible thymomas. One methylcholanthrene-induced sarcoma and 1 “spontaneous” mammary carcinoma were the only nonpolyoma tumors susceptible to the resistance effect. Another methylcholanthrene-induced sarcoma not susceptible to the resistance effect became susceptible after infection with polyoma virus in vitro. This finding suggests that the exceptional transplantation behavior of the 2 nonpolyoma tumors might be caused by an accidental virus contamination before they were tested. It was shown that the resistance effect is really induced by the polyoma virus and not by any other constituent of the virus-containing material. Medium from uninfected mouse embryonic cell cultures induced no resistance, a partially purified virus preparation was as effective as unpurified virus, and the resistance-inducing capacity was detected even after dilution 10−4 to 10−5 of the virus-containing material. There was a good correlation between the induction of antiviral antibodies in the recipients and the transplantation resistance effect in these animals.
SELECTIONS.
Authors: Geo. F. Payne
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erythroleukemia (di Guglielmo's disease). Occurrence 28 years after thorium administration
Authors: C. C. Waddell
Journal: JAMA (1977)

ERYTHROLEUKEMIA (Di Guglielmo's disease) is considered to be a variant of acute myeloblastic leukemia in which the bone marrow contains increased numbers of abnormal, bizarre erythroid precursors as well as increased numbers of myeloblasts. The development of acute leukemia (predominantly but not exclusively myeloblastic) after exposure to various forms of ionizing irradiation is well known. A few cases of leukemia occurring after intravenous injection of thorium dioxide (Thorotrast) have been reported.<sup>1</sup>We saw a patient who had PAS-positive erythroleukemia with chromosomal hypodiploidy 28 years after he had received thorium dioxide as a radiographic contrast agent. <h3>Report of a Case</h3> A 56-year-old man was hospitalized for fever of three weeks' duration. Results of physical examination on admission were unremarkable. Initial CBC count showed a hematocrit concentration of 32%; platelets, 85,000/cu mm; and WBCs, 5500/cu mm, with 4% neutrophils, 28% eosinophils, 68% atypical lymphocytes, and 28 nucleated RBCs per 100 WBCs.
Impedance Plethysmography and DVT Diagnosis
Authors: Paul R. Marantz
Journal: Annals of Internal Medicine (1993)

Letters1 August 1993Impedance Plethysmography and DVT DiagnosisPaul R. Marantz, MD and Alan Dresner, MDPaul R. Marantz, MDSearch for more papers by this author and Alan Dresner, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-3-199308010-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In their study of the diagnostic utility of impedance plethysmography (IPG), Anderson and colleagues [1] ignored the first guideline for evaluating a diagnostic test, namely, the need for an independent, blind comparison with a gold standard of diagnosis [2]. Although the gold standard of venography was sensibly used in this study, it was supplemented by compression ultrasonography in a handful of patients, for reasons that are not described. Even so, neither test was done in 242 of 386 patients because venography was done only if the IPG result was positive (or if a high clinical suspicion was ...References1. Anderson DR, Lensing AW, Wells PS, Levine MN, Weitz JI, Hirsh J. Limitations of impedance plethysmography in the diagnosis of clinically suspected deep-vein thrombosis. Ann Intern Med. 1993; 118:25-30. Google Scholar2. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Boston: Little, Brown; 1991:51-68. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1993Volume 119, Issue 3Page: 246-247KeywordsDatabasesNegative predictive valuePopulation statisticsPositive predictive valueSafetySpecificityThrombosisUltrasound imaging Issue Published: 1 August 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Ulcers and gastritis
Authors: H. Kashiwagi
Journal: Endoscopy (2008)

Chronic atrophic gastritis (CAG) plays a crucial role in the development of intestinal-type gastric carcinoma. Helicobacter pylori infection seems to be the main cause of CAG. Diagnosis of CAG is based mostly on gastroscopy and histological findings following gastric biopsy, which is difficult to apply in large-scale population-based studies. An approach more suitable for such studies is to obtain information on the gastric mucosal status by measuring pepsinogen (PG) concentrations in the blood, as has been developed by Miki et al. [2] and Samloff et al. [3]. The objectives of this study by Weck et al. were to estimate prevalence of CAG by using two diagnostic criteria and to examine the association between CAG and potential risk factors and clinical consequences in a large population-based study among elderly individuals in Germany. From the variety of cut-off points used to define CAG in previous epidemiological studies, the following two were chosen: (i) PG I < 25 ng/mL, which was used in the EUROGAST study by Webb et al. [4], the only large international comparative study to delineate severe forms of CAG; and (ii) PG I < 70 ng/mL and PG I/PG II < 3, as used in several studies from Japan to define any form of CAG. With the definition used in the EUROGAST study (PG I < 25 ng/mL), prevalence of CAG increased from 4.8 % in the age group 50 – 54 years to 8.7 % in the age group 70 – 74 years. The alternative definition of CAG (PG I < 70 ng/mL and PG I/PG II < 3) used in the Japanese studies, revealed a greater increase with age (from 2.7 % to 9.1 %) and a strong association with H. pylori infection. Prevalence of CAG was found to be at a low level in this large study of older adults in Germany, and strongly increased with age but was unrelated to sex, smoking, and alcohol consumption. A strong association with H. pylori infection emerged only when CAG was defined by both PG I and the PG I/PG II ratio. Therefore, the role of H. pylori infection may be underestimated in studies where CAG is defined only by PG I levels, supporting the use of the PG I/PG II ratio for the definition of CAG in epidemiological studies.
Smartphone
Authors: Martin Bernhard Wolf, Thomas Klose, Michael Putzker, Oliver Buchta
Journal: Journal of Clinical Oncology (2014)

e17534 Background: The German health care system, while a paradigm for other developed Western nations, nevertheless creates substantial costs that must not be borne by the patient. Little attention has been paid to patient compliance, however, costs associated with patient follow-up visits total an estimated €19 billion a year (2011) in Germany, and $290 billion a year in the U.S. (2009), offering an enormous savings potential. The rise of chronic disease has resulted in demographic shifts that mandate new strategies for improving counseling and support. Methods: An application for mobile devices may optimize patient compliance by providing the following features: (i) Reminders to support the regular use of medication,check ups and vaccination recommendations; (ii) Advice regarding medication intake and adverse reactions; (iii) Preparation of a medication dosage schedule; and (v) the ability to track and store medical diagnostic and patient data for patients with certain issues (e.g. weight, BMI, blood pressure, glucose and lipid levels, complete blood counts for patients with diabetes, high blood pressure, and/or cancer). A survey of ten questions was designed to test the acceptance of such a tool. Results: The survey of 123 patients conducted in January 2014 in a medium-sized German pharmacy showed that about 1/3 of the participants had problems with their medication. Almost 3/4 of the participants relied solely on their memory, only about 1/10 received help from outsiders, and that a technical tool would appeal to 1/3. Half of the respondents were smartphone users (iOS, Android OS), and a fifth of those users responded that they would be willing to use a fee-based
Abstract 829: SOX2-mediated 5hmC dysregulation in GBM stem cells
Authors: Sweta Sudhir, Hernando Lopez-Bertoni, Maria Lugo-Fagundo, Bachchu Lal, John Laterra
Journal: Cancer Research (2019)

Abstract Primary brain tumors are among the most devastating forms of cancer and glioblastoma (GBM) represents the most aggressive and lethal form of the disease. We now know that GBM contains small subsets of cells that display tumor-propagating stem-like phenotypes (i.e. glioma stem cells or GSCs) that act as critical determinants of resistance to current treatments and tumor recurrence for which there is no proven therapy. Altered patterns of DNA methylation are widely reported in human GBM. However, substantial knowledge gaps remain in our understanding of the molecular mechanisms responsible for this epigenetic dysregulation, its downstream consequences and its role in the GBM tumor-propagating phenotype. Understanding and ultimately targeting the epigenetic mechanisms that induce and maintain these tumor-propagating cell subsets is critical to improving GBM therapy and patient outcomes. DNA methylation generally occurs in cytosine-guanine (CpG) sequences and is established by DNMTs, which catalyze the conversion of cytosine to 5-methylcytosine (5mC). DNA methylation is dynamically regulated and reversible by the ten-eleven translocation (TET) family of deoxygenases that catalyze the conversion of 5mC to 5-hydroxymethylcytosine (5hmC). Levels of 5hmC closely align with the differentiation state of cells; terminally differentiated cells contain high levels of 5hmC and less differentiated cells have very low levels. Multiple studies found negative correlations between 5hmC levels and glioma grade and loss of 5hmC correlates with poor prognosis of GBM patients. This strongly suggests that tumor suppressing epigenetic mechanisms are driven by TET-dependent 5hmC generation. We now show that SOX2, a reprogramming transcription factor that induces GSCs, represses the TET2 and decreases 5hmC in multiple GSC isolates. TET2 repression using two independent shRNA hairpins efficiently decreased 5hmc levels and significantly enhanced self-renewal capacity and tumor growth capacity of low-passage GSCs. We also show that low concentrations of vitamin C, a TET enzyme cofactor, significantly increases 5hmC in low-passage GSCs. This epigenetic change induced by vitamin C associated with increased GSC death induced by temozolomide (TMZ), the main chemotherapeutic used to treat GBM. These findings support a mechanism by which SOX2 induces loss of 5hmC in GSCs by repressing TET2 and show that vitamin C can reverse this epigenetic tumor promoting pathway and potentially enhance GBM chemotherapeutics. Citation Format: Sweta Sudhir, Hernando Lopez-Bertoni, Maria Lugo-Fagundo, Bachchu Lal, John Laterra. SOX2-mediated 5hmC dysregulation in GBM stem cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 829.
Chemical Prevention of Tumor Spread?
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal